Bemfola

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

follitropin alfa

Available from:

Gedeon Richter Plc.

ATC code:

G03GA05

INN (International Name):

follitropin alfa

Therapeutic group:

Spolni hormoni i modulatori genitalnog sustava,

Therapeutic area:

anovulacija

Therapeutic indications:

In adult women:anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT);follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. U kliničkim istraživanjima kod ovih pacijenata su identificirani endogene razina LH u serumu < 1. 2 IU / l. In adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.

Product summary:

Revision: 10

Authorization status:

odobren

Authorization date:

2014-03-26

Patient Information leaflet

                                39
B. UPUTA O LIJEKU
40
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
BEMFOLA 75 IU/0,125 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ BRIZGALICI
BEMFOLA 150 IU/0,25 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ BRIZGALICI
BEMFOLA 225 IU/0,375 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ BRIZGALICI
BEMFOLA 300 IU/0,50 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ BRIZGALICI
BEMFOLA 450 IU/0,75 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ BRIZGALICI
Folitropin alfa
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
_ _
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Bemfola i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati lijek Bemfola
3.
Kako primjenjivati lijek Bemfola
4.
Moguće nuspojave
5.
Kako čuvati lijek Bemfola
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE BEMFOLA I ZA ŠTO SE KORISTI
ŠTO JE BEMFOLA
Ovaj lijek sadrži djelatnu tvar folitropin alfa, koji je gotovo
identičan prirodnom hormonu koji stvara
Vaše tijelo, naziva „folikulostimulirajući hormon“ (FSH). FSH je
gonadotropin, tip hormona koji ima
važnu ulogu u ljudskoj plodnosti i reprodukciji. U žena, FSH je
potreban za rast i razvoj vrećica
(folikula) u jajnicima koje sadrže jajne stanice. U muškaraca, FSH
je potreban za proizvodnju sperme.
ZA ŠTO SE BEMFOLA KORISTI
U ODRASLIH ŽENA
Bemfola se koristi:
•
za poticanje oslobađanja jajne stanice iz jajnika (ovulacije) u žena
koje ne ovuliraju i koje nisu
odgovorile na terapiju lijekom „klomifencitrat“.
•
zajedno s još jednim hormonom, „lutropinom alfa“
(„luteinizirajući hormon“ 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Bemfola 75 IU/0,125 ml otopina za injekciju u napunjenoj brizgalici
Bemfola 150 IU/0,25 ml otopina za injekciju u napunjenoj brizgalici
Bemfola 225 IU/0,375 ml otopina za injekciju u napunjenoj brizgalici
Bemfola 300 IU/0,50 ml otopina za injekciju u napunjenoj brizgalici
Bemfola 450 IU/0,75 ml otopina za injekciju u napunjenoj brizgalici
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedan ml otopine sadrži 600 IU (što odgovara 44 mikrograma)
folitropina alfa*.
Bemfola 75 IU/0,125 ml otopina za injekciju u napunjenoj brizgalici
Jedna napunjena brizgalica osigurava primjenu 75 IU (što odgovara 5,5
mikrograma) u 0,125 ml.
Bemfola 150 IU/0,25 ml otopina za injekciju u napunjenoj brizgalici
Jedna napunjena brizgalica osigurava primjenu 150 IU (što odgovara 11
mikrograma) u 0,25 ml.
Bemfola 225 IU/0,375 ml otopina za injekciju u napunjenoj brizgalici
Jedna napunjena brizgalica osigurava primjenu 225 IU (što odgovara
16,5 mikrograma) u 0,375 ml.
Bemfola 300 IU/0,50 ml otopina za injekciju u napunjenoj brizgalici
Jedna napunjena brizgalica osigurava primjenu 300 IU (što odgovara 22
mikrograma) u 0,5 ml.
Bemfola 450 IU/0,75 ml otopina za injekciju u napunjenoj brizgalici
Jedna napunjena brizgalica osigurava primjenu 450 IU (što odgovara 33
mikrograma) u 0,75 ml.
* rekombinantni humani folikulostimulirajući hormon (r-hFSH),
proizveden u stanicama jajnika
kineskog hrčka (CHO) tehnologijom rekombinantne DNK.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za injekciju (injekcija).
Bistra, bezbojna otopina.
pH otopine je 6,7 do 7,3.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
U odraslih žena
•
Anovulacija (uključujući sindrom policističnih jajnika) u žena
koje ne reagiraju na terapiju
klomifencitratom.
•
Stimulacija razvoja većeg broja folikula u žena kod kojih se
stimulira superovulacija za metode
medicinski potpomognute oplodnje kao što su
_in vitro_
umjetna oplodnja (IVF), transfer gamete
u jajovod i transfer zi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-01-2024
Public Assessment Report Public Assessment Report Bulgarian 16-05-2014
Patient Information leaflet Patient Information leaflet Spanish 17-01-2024
Public Assessment Report Public Assessment Report Spanish 16-05-2014
Patient Information leaflet Patient Information leaflet Czech 17-01-2024
Public Assessment Report Public Assessment Report Czech 16-05-2014
Patient Information leaflet Patient Information leaflet Danish 17-01-2024
Public Assessment Report Public Assessment Report Danish 16-05-2014
Patient Information leaflet Patient Information leaflet German 17-01-2024
Public Assessment Report Public Assessment Report German 16-05-2014
Patient Information leaflet Patient Information leaflet Estonian 17-01-2024
Public Assessment Report Public Assessment Report Estonian 16-05-2014
Patient Information leaflet Patient Information leaflet Greek 17-01-2024
Public Assessment Report Public Assessment Report Greek 16-05-2014
Patient Information leaflet Patient Information leaflet English 17-01-2024
Public Assessment Report Public Assessment Report English 16-05-2014
Patient Information leaflet Patient Information leaflet French 17-01-2024
Public Assessment Report Public Assessment Report French 16-05-2014
Patient Information leaflet Patient Information leaflet Italian 17-01-2024
Public Assessment Report Public Assessment Report Italian 16-05-2014
Patient Information leaflet Patient Information leaflet Latvian 17-01-2024
Public Assessment Report Public Assessment Report Latvian 16-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-01-2024
Public Assessment Report Public Assessment Report Lithuanian 16-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 17-01-2024
Public Assessment Report Public Assessment Report Hungarian 16-05-2014
Patient Information leaflet Patient Information leaflet Maltese 17-01-2024
Public Assessment Report Public Assessment Report Maltese 16-05-2014
Patient Information leaflet Patient Information leaflet Dutch 17-01-2024
Public Assessment Report Public Assessment Report Dutch 16-05-2014
Patient Information leaflet Patient Information leaflet Polish 17-01-2024
Public Assessment Report Public Assessment Report Polish 16-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 17-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 17-01-2024
Public Assessment Report Public Assessment Report Portuguese 16-05-2014
Patient Information leaflet Patient Information leaflet Romanian 17-01-2024
Public Assessment Report Public Assessment Report Romanian 16-05-2014
Patient Information leaflet Patient Information leaflet Slovak 17-01-2024
Public Assessment Report Public Assessment Report Slovak 16-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 17-01-2024
Public Assessment Report Public Assessment Report Slovenian 16-05-2014
Patient Information leaflet Patient Information leaflet Finnish 17-01-2024
Public Assessment Report Public Assessment Report Finnish 16-05-2014
Patient Information leaflet Patient Information leaflet Swedish 17-01-2024
Public Assessment Report Public Assessment Report Swedish 16-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 17-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 17-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 17-01-2024

Search alerts related to this product

View documents history